NCT07327411 2026-01-08
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT04685473 2025-04-09
Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors
Taivex Therapeutics Corporation
Phase 1 Active not recruiting
NCT03863145 2024-02-07
Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors
Cosmo Pharmaceuticals NV
Phase EARLY_PHASE1 Recruiting
NCT03195764 2022-11-18
Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
Taivex Therapeutics Corporation
Phase 1 Terminated
NCT03349073 2022-11-18
An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
Taivex Therapeutics Corporation
Phase 1 Completed
NCT04324372 2022-08-12
Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors
Sunshine Lake Pharma Co., Ltd.
Phase 1 Completed
NCT04892498 2022-08-09
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04200404 2022-05-06
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
CStone Pharmaceuticals
Phase 1/2 Completed
NCT02300467 2015-08-14
NOV120401 (CKD-516 Tablet) for Advanced Solid Tumors
National OncoVenture
Phase 1 Unknown
NCT01762410 2014-09-29
Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
Piramal Enterprises Limited
Phase 1 Suspended
NCT01779336 2014-09-29
Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors
Piramal Enterprises Limited
Phase 1 Suspended